更新于：2024-12-04
Amlodipine Besylate/Benazepril Hydrochloride
氨氯地平贝那普利
更新于：2024-12-04
概要
基本信息
药物类型 小分子化药 |
别名 Amlodipine Besylate and Benazepril Hydrochloride、Amlodipine/benazepril、Lotrel + [1] |
作用机制 ACE抑制剂(血管紧张素转化酶抑制剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-03-03), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C24H29ClN2O5 |
InChIKeyVPSRQEHTHIMDQM-FKLPMGAJSA-N |
CAS号86541-74-4 |
查看全部结构式(2)
关联
39
项与 氨氯地平贝那普利 相关的临床试验左氨氯地平贝那普利胶囊（2.5mg /10mg）用于盐酸贝那普利片（10mg）单药治疗4周血压不能有效控制的原发性轻、中度高血压患者的有效性和安全性的随机、双盲双模拟、多中心III期临床研究
氨氯地平贝那普利胶囊在健康受试者中随机、开放、单剂量、两制剂、交叉对照空腹及餐后状态下的生物等效性研究
氨氯地平贝那普利胶囊（5mg:10mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两制剂、交叉生物等效性试验
100 项与 氨氯地平贝那普利 相关的临床结果
登录后查看更多信息
100 项与 氨氯地平贝那普利 相关的转化医学
登录后查看更多信息
100 项与 氨氯地平贝那普利 相关的专利（医药）
登录后查看更多信息
11
项与 氨氯地平贝那普利 相关的文献（医药）2022-09-01Annals of palliative medicine
Hypertension as a rare adverse effect caused by infliximab in the treatment of Crohn’s disease: a case report
作者: Mo, Jiahao ; Zhao, Xiying ; Tang, Jian ; Zhang, Beiping
BACKGROUND:
Infliximab is an effective drug for the treatment of Crohn's disease. As a rare and unique adverse effect of infliximab, hypertension should be paid enough attention in clinical work. At present, there is no relevant case report. We report a case of a 38-year-old man with Crohn's disease who had no history of hypertension and developed hypertension symptoms during infliximab treatment.
CASE DESCRIPTION:
The patient was treated with 5 mg/kg infliximab on August 27, 2020. From August 27, 2020 to October 20, 2020, the patient underwent 3 treatment sessions. After each injection of infliximab, the patient's blood pressure became elevated, accompanied by dizziness and symmetrical numbness of both lower limbs. Amlodipine benazepril tablets were given orally to control blood pressure. Under close monitoring, 5 mg/kg infliximab was used again. After 10 min of infusion, blood pressure rose to 160/118 mmHg. Infusion was discontinued immediately, after which blood pressure decreased to normal. Adrenal computed tomography did not indicate adrenal hyperplasia or space occupying lesions, and the detection of hypertension related indicators in standing and supine position was abnormal. Since follow up, the patient has stopped using infliximab and has had no hypertension-related symptoms, even without antihypertensives. Measured blood pressure was within the normal range.
CONCLUSIONS:
Hypertension, as one of the rare adverse reactions of infliximab in the treatment of Crohn's disease, should be paid enough attention.
2013-07-01American journal of hypertension3区 · 医学
Dynamic View on Affordability of Fixed-Dose Combination Antihypertensive Drug Therapy
3区 · 医学
Article
作者: Junling Wang ; Jun Tang ; Song Hee Hong
BACKGROUND:
The use of fixed-dose combinations (FDCs) has been increasing since the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended using ≥2 drugs as the first-line drug therapy for patients with stage 2 hypertension. FDCs simplify the drug therapy regimen and reportedly lower the drug therapy cost compared with the free combination (FC) of 2 single-agent drugs. This study hypothesized that the affordability of FDCs over FCs would change over time depending on the availability of generic single-agent drugs.
METHODS:
This study used the 2009 Medical Expenditure Panel Survey. Antihypertensive drugs were identified based on the Food and Drug Administration national drug directory. Based on the 2 databases, regression models were run to predict average monthly drug cost as well as out-of-pocket cost for each prescription along with their 95% confidence intervals (CIs).
RESULTS:
Overall, FDCs (n = 26) had average monthly drug costs similar to respective FCs when FCs were not generically available. However, when FCs were generically available, FDCs (n = 11) had average drugs costs much higher than their respective FCs. For example, Lotrel as an FDC had an average monthly drug cost of $115.97 (95% CI = $96.59-$135.36), whereas its counterpart FC had an average monthly drug cost of $21.00 (95% CI = $18.23-$23.79).
CONCLUSIONS:
The cost advantage of FDCs over FCs was reversed when FCs were generically available. The finding of this study informs patients, health-care providers, and drug plans of the importance of making dynamic decisions on preferred drug therapy options depending on the availability of generic drugs.
2011-06-01Expert review of cardiovascular therapy
Renoprotective effects of benazepril: current perspective
Review
作者: Olszewski, Artur ; Stompoor, Tomasz ; Napora, Maria
Cardiovascular (CV) disease, its associated risk factors and continued progression run in parallel with renal deterioration (cardio-renal syndrome). Most guidelines promote early treatment, including the use of ACE inhibitors to control CV risk in patients with chronic renal failure. The renoprotective effects of the ACE inhibitor, benazepril, independent of blood pressure control, have been demonstrated, as monotherapy or in combination with amlodipine or hydrochlorothiazide, in large clinical trials: Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) and Gauging Albuminuria Reduction with Lotrel in Diabetic Patients with Hypertension (GUARD) in patients with mild-to-severe chronic kidney disease. In the ACCOMPLISH trial, CV outcomes and renoprotective effects were greater in patients receiving benazepril in combination with amlodipine; the GUARD trial demonstrated that combined benazepril/hydrochlorothiazide was more effective than amlodipine combined with benazepril in reducing baseline urinary albumin:creatinine ratio and normalizing urinary albumin:creatinine ratio in patients with baseline microalbuminuria, although this effect was accompanied with a greater decrease in glomerular filtration rate than with benazepril/amlodipine. While this is not a study in patients with overt renal disease (patients had severe CV diseases), the ACCOMPLISH trial is the first large study to date to show the added benefit of combining ACE inhibitors and calcium-channel blockers in renal protection. Future large, well-controlled trials, designed to evaluate hard renal outcomes, are required to identify which patients will benefit most from particular combination treatment strategies in renoprotection.
100 项与 氨氯地平贝那普利 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 美国 | 1995-03-03 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 226 | 艱繭顧壓襯衊願廠窪蓋(膚築餘餘淵鹹繭遞窪簾) = more frequently reported in the amlodipine/benazepril group than in the valsartan/hydrochlorothiazide group 醖餘觸淵膚壓襯鑰簾鏇 (鹹遞襯積製鏇遞窪蓋窪 ) | - | 2012-08-01 | |||
临床3期 | 11,506 | (Benazepril/Amlodipine) | 窪膚糧蓋夢鹹襯製鑰廠(憲繭醖窪鬱壓遞夢衊窪) = 醖範糧餘艱廠鹽網獵網 簾壓構壓願衊範繭膚窪 (膚構壓繭壓網鏇鏇衊齋, 醖選鏇膚窪簾齋鬱襯鑰 ~ 鑰選願繭鏇獵廠夢鬱壓) 更多 | - | 2011-05-17 | ||
(Benazepril/Hydrochlorothiazide) | 窪膚糧蓋夢鹹襯製鑰廠(憲繭醖窪鬱壓遞夢衊窪) = 簾壓獵窪夢鏇壓糧鹽鬱 簾壓構壓願衊範繭膚窪 (膚構壓繭壓網鏇鏇衊齋, 獵願餘膚襯簾鹹蓋構糧 ~ 襯網憲製衊鬱網壓構壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用